Merck & Co. Inc. has launched Renflexis (infliximab-abda), the company announced July 24, marking the first time two biosimilars will compete against a brand drug in the US. Renflexis is the second biosimilar version of Johnson & Johnson's blockbuster anti-TNF Remicade (infliximab) to reach the US market behind Pfizer Inc.'s Inflectra (infliximab-dyyb).
Merck appears to be competing aggressively on price, which will be welcome news to payers. The company set the wholesale...
Welcome to Scrip
Create an account to read this article
Already a subscriber?